ISOFOL Stock Overview
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Isofol Medical AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.76 |
52 Week High | kr1.24 |
52 Week Low | kr0.45 |
Beta | 1.48 |
1 Month Change | 31.14% |
3 Month Change | 26.33% |
1 Year Change | 28.04% |
3 Year Change | -96.11% |
5 Year Change | -96.98% |
Change since IPO | -97.19% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued
May 18Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation
Nov 09Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?
May 12Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)
Apr 08Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment
Mar 03We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully
Jan 10Shareholder Returns
ISOFOL | SE Biotechs | SE Market | |
---|---|---|---|
7D | 3.6% | 1.4% | 1.9% |
1Y | 28.0% | 5.1% | 17.1% |
Return vs Industry: ISOFOL exceeded the Swedish Biotechs industry which returned 6.3% over the past year.
Return vs Market: ISOFOL exceeded the Swedish Market which returned 19% over the past year.
Price Volatility
ISOFOL volatility | |
---|---|
ISOFOL Average Weekly Movement | 17.1% |
Biotechs Industry Average Movement | 8.9% |
Market Average Movement | 6.1% |
10% most volatile stocks in SE Market | 12.9% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ISOFOL's share price has been volatile over the past 3 months.
Volatility Over Time: ISOFOL's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 3 | Petter Lindqvist | https://isofolmedical.com |
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm.
Isofol Medical AB (publ) Fundamentals Summary
ISOFOL fundamental statistics | |
---|---|
Market cap | kr122.43m |
Earnings (TTM) | -kr37.07m |
Revenue (TTM) | kr721.00k |
169.8x
P/S Ratio-3.3x
P/E RatioIs ISOFOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ISOFOL income statement (TTM) | |
---|---|
Revenue | kr721.00k |
Cost of Revenue | kr35.14m |
Gross Profit | -kr34.41m |
Other Expenses | kr2.66m |
Earnings | -kr37.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
Earnings per share (EPS) | -0.23 |
Gross Margin | -4,773.23% |
Net Profit Margin | -5,141.61% |
Debt/Equity Ratio | 0% |
How did ISOFOL perform over the long term?
See historical performance and comparison